Corporate News Report
Orexo (ORX.ST) closed the trading session of Friday 23 September 2026 08:33 PM Central Europe with a modest decline of 0.37 %. At the close, a single share traded at approximately SEK 5.20 on the primary exchanges. The company currently issues 35.1 million shares, yielding a market capitalization of SEK 187.9 million. In the preceding 24 hours, the volume of Orexo shares exchanged was roughly SEK 310 000, a fraction of the 200‑day simple moving average, which sits at SEK 19.98. Over the last year, the share price has fallen 57.14 %, a sharp downturn relative to its 52‑week high of SEK 36.00 on 1 September 2026 and the 52‑week low of SEK 5.30 on 21 October 2026.
Third‑Quarter Performance and Strategic Outlook
Orexo AB reported a challenging third‑quarter 2026. The company’s post‑tax result was negative, with earnings per share reflecting a comparable decline. The adverse outcome was largely attributed to restructuring costs and a settlement reached with the U.S. Department of Justice. Despite the headwinds, Orexo maintains a clear focus on navigating the heightened regulatory scrutiny and cost‑control pressures that accompany its specialized pharmaceutical operations. Management remains committed to stabilising the financial position while continuing to invest in product development and compliance initiatives.
Peer Comparison: 24‑Hour Activity
| Stock | 24‑Hour Change | Current Price | Market Cap | Notes |
|---|---|---|---|---|
| Vnv Global (VNV.ST) | +0.66 % | SEK 19.16 | SEK 222.6 million | Strong third‑quarter turnover, improved margins, new revolving credit facility. |
| Orron Energy (ORRON.ST) | 0 % | SEK 7.75 | SEK 219.1 million | Flat performance. |
| Kebni (KEBNIB.ST) | 0 % | SEK 0.65 | SEK 217.3 million | Flat performance. |
| Tura (8WO.F) | 0 % | EUR 0.36 | EUR 20 million | Flat performance, P/E 21.68. |
| Lammhults Design (LAMM-B.ST) | +2.58 % | SEK 28.10 | SEK 207.1 million | Steady third‑quarter sales, rising order intake, improved operating profit. |
About Orexo
Orexo AB is headquartered in Uppsala, Sweden, and specializes in the development of advanced drug‑delivery technologies, with a particular emphasis on opioid addiction and pain management therapies. Since its initial public offering on 9 November 2005, the company has grown into a global player serving customers worldwide. Further details on Orexo’s activities and product pipeline are available on its website at www.orexo.se .